Abstract
The gut microbiota is pivotal in regulating host metabolism, immune signaling, and the integrity of the mucosal barrier, thus serving as a critical factor in various metabolic, inflammatory, and gastrointestinal disorders. Traditional probiotics, primarily comprising Lacticaseibacillus and Bifidobacterium species, have been utilized to enhance gut health; however, the strain-dependent effects and variable clinical outcomes associated with these probiotics have prompted increased interest in next-generation probiotics (NGPs). Akkermansia muciniphila, a commensal organism that degrades mucin and resides at the mucosal interface, has emerged as a prominent NGP owing to its ability to reinforce epithelial integrity, modulate immune responses, and foster metabolic homeostasis. Of particular significance is its surface protein, Amuc_1100, which acts as a parabiotic molecule. This protein engages host pattern-recognition pathways, bolsters tight-junction proteins, and alleviates low-grade inflammation. In contrast to live bacterial formulations, purified Amuc_1100 presents advantages concerning stability, safety, and regulatory compliance. This review aims to synthesize contemporary insights into gut microbiome functionality while comparing traditional probiotics with next-generation alternatives. Additionally, it delineates the therapeutic potential of A. muciniphila and Amuc_1100. The discussion further encompasses clinical advancements, regulatory frameworks, and formulation considerations that are propelling the shift towards mechanism-based microbiome therapeutics.